Allos Therapeutics, Inc.’s Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer by the European Commission

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today that the European Medicines Agency (EMEA), with a positive opinion of the Committee for Orphan Medicinal Products, has granted orphan medicinal product designation to the Company’s novel antifolate, pralatrexate, for the treatment of non-papillary transitional cell carcinoma (TCC) of the urinary bladder, a form of bladder cancer. The Company is currently investigating pralatrexate in a Phase 2 study in patients with advanced or metastatic relapsed TCC of the urinary bladder. In April 2007, the EMEA granted orphan drug designation to pralatrexate for the treatment of patients with peripheral T-cell lymphoma.

Back to news